The Use of Solubilizing Excipients and Approaches to Generate Toxicology Vehicles for Contemporary Drug Pipelines

  • MARCUS E. BREWSTER
  • CLAIRE MACKIE
  • MARC NOPPE
  • ANN LAMPO
  • THORSTEINN LOFTSSON
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VI)

Abstract

The purpose of this chapter is two-fold and includes approaches for identifying potentially problematic drug candidates with regard to formulation, in general, and for the preparation of toxicology vehicles, in particular. In addition, an attempt is made to provide insight as to what oral and parenteral excipients are appropriate for early human testing and, by extension, which of these materials can reasonably be used in GLP toxicology evaluation intended to support these Phase I human assessments. These considerations are becoming more visible in the drug development arena as evidenced by a number of recent symposia and congresses (Liu 2005; Van Gelder, 2006).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agoram B, Woltosz W, and Bolger M. Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Absorption. Adv Drug Deliv Rev 2001; 50: S41–S67.PubMedGoogle Scholar
  2. Akers MJ. Excipient-Drug Interactions in Parenteral Formulations. J Pharm Sci 2002; 91: 2283–2300.PubMedGoogle Scholar
  3. Akkar A and Müller RH. Intravenous Itraconazole Emulsions Produced by SolEmuls Technology. Eur J Pharm Biopharm 2003; 56: 29–36.PubMedGoogle Scholar
  4. Amidon GL, Lennernas H, Shah VP, and Crison JR. Theoretical Basis for a Biopharmaceutical Drug Classification: The Correlation of in vitro Drug Product Dissolution and in vivo Bioavailability.Pharm Res 1995; 12: 413–420.PubMedGoogle Scholar
  5. Amidon G and Williams NA. A Solubility Equation for Non-Electrolytes in Water. Int J Pharm 1982; 11: 249–256.Google Scholar
  6. Apple LE, Babcock WC, Friesen DT, Ray RJ, Shamblin RM, and Smithey DT. Pharmaceutical Dosage Forms Comprising a Low Solubility Drug and Polymer. International Patent Appl 2006: WO2006024944 A2.Google Scholar
  7. Ash M and Ash I. Handbook of Pharmaceutical Additives. Gower Publishing Ltd, Hampshire, UK, 1997.Google Scholar
  8. Avdeef A. The Rise of PAMPA. Expert Opin Drug Metab Toxicol 2005; 1: 325–342.PubMedGoogle Scholar
  9. Balbach S and Korn C. Pharmaceutical Evaluation of Early Developmental Candidates “The 100 mg Approach.” Int J Pharm 2004; 275: 1–12.PubMedGoogle Scholar
  10. Bergstrom CAS, Strafford M, Lazorova L, Avdeef A, Luthman K, and Artursson P. Absorption Classification of Oral Drugs Based on Molecular Surface Properties. J Med Chem 2003; 46: 558–570.PubMedGoogle Scholar
  11. Bittner B and Mountfield RJ. Formulation and Related Activities for the Oral Administration of Poorly Water-Soluble Compounds in Early Discovery Animal Studies: An Overview of Frequently Applied Approaches Part 1. Pharmazeut Indust 2002; 64: 800–807.Google Scholar
  12. Bittner B and Mountfield RJ. Formulation and Related Activities for the Oral Administration of Poorly Water-Soluble Compounds in Early Discovery Animal Studies: An Overview of Frequently Applied Approaches Part 2. Pharmazeut Indust 2002a; 64: 985–991.Google Scholar
  13. Bittner B and Mountfield RJ. Intravenous Administration of Poorly Soluble New Drug Entities in Early Drug Discovery: The Potential Impact of Formulation on Pharmacokinetic Parameters. Curr Opin Drug Disc Dev 2002b; 5: 59–71.Google Scholar
  14. Blasko A, Leahy-Dios A, Nelson W, Austin S, Killion R, Visor G, and Massey I. Revisiting the Solubility Concept of Pharmaceutical Compounds. Monat Chem 2001; 132: 789–798.Google Scholar
  15. Box KJ, Volgyi G, Baka E, Stuart M, Takacs-Novak K, and Comer J. Equilibration Versus Kinetic Measurements of Aqueous Solubility and the Ability of Compounds to Supersaturate in Solution—A Validation Study. J Pharm Sci 2006; 95: 1298–1307.PubMedGoogle Scholar
  16. Brewster ME, Simpkins JW, Hora MS, Stern WC, and Bodor N. Review: Potential Use of Cyclodextrins in Parenteral Formulations.J Parent Sci Technol 1989; 43: 231–240.Google Scholar
  17. Brewster ME, Verreck G, Chun I, Rosenblatt J, Mensch J, Van Dijck A, Noppe M, Arien T, Bruining M, and Peeters J. The Use of Polymer-Based Electrospun Nanofibers Containing Amorphous Drug Dispersions in the Delivery of Poorly Water-Soluble Pharmaceuticals. Die Pharmazie 2004; 59: 387–391.PubMedGoogle Scholar
  18. Burton P, Goodwin JT, Vidmar TJ, and Amore BM. Predicting Drug Absorption: How Nature Made it a Difficult Problem. J Pharm Exp Therap 2002; 303: 889–895.Google Scholar
  19. Camenisch G, Alsenz J, Van de Waterbeemd H, and Folkers G. Estimation of Permeability by Passive Diffusion through Caco-2 Cell Monolayers Using the Drug's Lipophilicity and Molecular Weight.Eur J Pharm Sci 1998; 6: 313–319.Google Scholar
  20. Challa R, Ahuja A, Ali J, and Khar RK. Cyclodextrin in Drug Delivery: An Updated Review. AAPS PharmSciTech 2005; 6: E329–E357.PubMedGoogle Scholar
  21. Chan K and Gibaldi M. Assessment of Drug Absorption after Oral Administration. J Pharm Sci 1985; 74: 388–393.PubMedGoogle Scholar
  22. Cheng C, Yu L, Lee H, Yang C, Lue C, and Chou C. Biowaiver Extension Potential to BCS Class III High Solubility-Low Permeability Drugs: Bridging Evidence for Metformin Immediate-release Tablet. Eur J Pharm Sci 2004; 22: 297–304.PubMedGoogle Scholar
  23. Crew MD, Shanker RM, Smithey DT, Miller WK, and Friesen DT. Stabilized Pharmaceutical Solid Compositions of Low Solubility Drugs, Poloxamers and Stabilizing Polymers. International Patent Appl 2005: WO 2005065656 A2.Google Scholar
  24. Curatolo W, Physical Chemical Properties of Oral Drug Candidates in the Discovery and Exploratory Development Setting. 1998; PSTT 1: 387–393.Google Scholar
  25. Dannenfelser R, He H, Joshi Y, Bateman S, and Serajuddin ATM. Development of Clinical Dosage Forms for a Poorly Water Soluble Drug I: Application of Polyethylene Glycol-Polysorbate 80 Solid Dispersion Carrier System. J Pharm Sci 2004; 93: 1165–1175.PubMedGoogle Scholar
  26. Davis ME and Brewster ME. Cyclodextrin-Based Pharmaceutics: Past, Present, Future. Nature Rev Drug Discov 2004; 3: 1023–1035.Google Scholar
  27. De Beule K and Van Gestel J. Pharmacology of Itraconazole. Drugs 2001; 61(Suppl. 1): 27–33.PubMedGoogle Scholar
  28. De Conde V, Gilis P, and Putteman P. Pellets having a Core Coated with a Lipid Lowering Agent and a Polymer. International Patent 1999: WO 9955313.Google Scholar
  29. Dehring KA, Workman H, Miller K, Mandagere A, and Poole S. Automated Robotic Liquid Handling/Laser-based System for High Throughput Measurement of Kinetic Aqueous Solubility. J Pharm Biomed Anal 2004; 35: 447–456.Google Scholar
  30. Dokoumetzidis A, Papadopoulou V, and Macheras P. Analysis of Dissolution Rate Using Modified Versions of Noyes-Whitney Equation and the Weibull Function. Pharm Res 2006; 23: 256–261.PubMedGoogle Scholar
  31. Dressman JB, Amidon G, Reppas C, and Shah VP. Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms. Pharm Res 1998; 15: 11–22.PubMedGoogle Scholar
  32. Dressman J, Butler J, Hempenstall J, and Reppas C. The BCS: Where do We go from Here? Pharm Tech 2001; 25: 68–76.Google Scholar
  33. FDA, Guidance for Industry. Q3C Impurities: Residual Solvents. http://www.fda.gov/cder/ guidance/Q3Cfinal.htm (Dated 1997).Google Scholar
  34. FDA, Guidance for Industry. Drug product—Chemistry, Manufacturing and Control Information. http://www.fda.gov/cder/guidance/1215dft.pdf (Dated 2003).Google Scholar
  35. FDA, Guidance for Industry. Q3C—Tables and List. http://www.fda.gov/ cder/guidance/Q3CT&Lrev1.pdf (Dated 2003a).Google Scholar
  36. FDA, Guidance for Industry. Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. http://www.fda.gov/cder/guidance/ 5544fnl.htm (Dated 2005).Google Scholar
  37. FDA, Center for Drug Evaluation and Research, Inactive Ingredient Database. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm (2006).Google Scholar
  38. FDA GRAS, Summary of All GRAS Notices. http://www.cfsan.fda.gov/~rdb/opa-gras. html (May 2006).Google Scholar
  39. Fiese EF. General Pharmaceutics—The New Physical Pharmacy. J Pharm Sci 2003; 92: 1331–1342.PubMedGoogle Scholar
  40. Gao P, Guyton ME, Huang T, Bauer J, Stefanski K, and Lu L. Enhanced Oral Bioavailability of a Poorly Water Soluble Drug PNU-91325 by Supersaturable Formulations. Drug Dev Ind Pharm 2004; 30: 221–229.PubMedGoogle Scholar
  41. Gao P, Hageman MJ, Morozowich W, Dalga RJ, Stefanski KJ, Huang T, Karim A, Hassan F, and Forbes, JC. Pharmaceutical Compositions Having Reduced Tendency for Drug Crystallization. International Patent Appl 2002: WO 02056878 A2.Google Scholar
  42. Gao P, Rush BD, Pfund WP, Huang T, Bauer JM, Morozowich W, KUO M, and Hageman MJ. Development of a Supersaturable SEDDS (S-SEDDS) Formulation of Paclitaxel with Improved Oral Bioavailability. J Pharm Sci 2003; 92: 2386–2398.PubMedGoogle Scholar
  43. Gardner CR, Walsh CT, and Almarsson O. Drugs as Materials: Valuing Physical Form in Drug Discovery. Nature Rev Drug Discov 2004; 3: 926–934.Google Scholar
  44. Gelderblom H, Verweij J, Nooter K, and Sparreboom A. Chrmophor EL: The Drawbacks and Advantages of Vehicle Selection for Drug Formulation. Eur J Cancer 2001; 37: 1591–1598.Google Scholar
  45. Gould S and Scott RC. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A Toxicological Review. Food Chem Toxicol 2005; 43: 1451–1459.PubMedGoogle Scholar
  46. Hidalgo I. Assessing the Absorption of New Pharmaceuticals. Curr Top Med Chem 2001; 1: 385–401.PubMedGoogle Scholar
  47. Hilde LR and Morris KR, Physics of Amorphous Solids. J Pharm Sci 2004; 93: 3–12.Google Scholar
  48. Horter D and Dressman JB. Influence of Physicochemical Properties on Dissolution of Drugs in the Gastrointestinal Tract. Adv Drug Deliv Rev 2001; 46: 75–87.PubMedGoogle Scholar
  49. Ingels F and Augustijns P. Biological, Pharmaceutical and Analytical Considerations with Respect to the Transport Media Used in the Absorption Screening System, Caco-2. J Pharm Sci 2003; 92: 1545–1558.PubMedGoogle Scholar
  50. International Pharmaceutical Excipients Council. IPEC, the International Pharmaceutical Excipients Council is the World-wide Trade Association of Manufacturers and Users of Pharmaceutical Excipients. http://www.ipec.org (2006).Google Scholar
  51. Jain N and Yalkowsky SH. Estimation of Aqueous Solubility I: Application to Organic Non-electrolytes. J Pharm Sci 2001; 9: 234–252.Google Scholar
  52. JECFA. Monographs, and Evaluation of the Joint WHO/FAO Expert Committee on Food Additives. http://www.inchem.org/pages/jecfa.html (2006).Google Scholar
  53. Johnson KC. Dissolution and Absorption Modeling: Model Expansion to Simulate the Effects of Precipitation, Water Absorption, Longitudinally Changing Intestinal Permeability, and Controlled Release on Drug Absorption. Drug Devlop Ind Pharm 2003; 29: 833–842.Google Scholar
  54. Johnson KC and Swindell AC. Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption. Pharm Res 1996; 1795–1798.Google Scholar
  55. Johnson S and Zheng W. Recent Progress in the Computational Prediction of Aqueous Solubility and Absorption. AAPS J 2006; 8: E27–E40.PubMedGoogle Scholar
  56. Jolivette L and Ward K. Extrapolation of Human Pharmacokinetic Parameters from Rat, Dog and Monkey Data: Molecular Properties Associated with Extrapolative Success or Failure. J Pharm Sci 2005; 94: 1467–1483.PubMedGoogle Scholar
  57. Jung S, Choi S, Um S, Kim J, Choo H, Choi S, and Chung S. Prediction of the Permeability of Drug through Study on Quantitative-Permeability Relationship. J Pharm Biomed Anal 2006; 41: 469–475.PubMedGoogle Scholar
  58. Kalantzi L, Reppas C, Dressman JB, Amidon G, Junginger HE, Midha KK, Shah VP, Stavchansky SA, and Barends DM, Biowaiver Monograph for Immediate Release Solid Dosage Forms: Acetominophen (Paracetamol). J Pharm Sci 2005; 95: 4–14.Google Scholar
  59. Kashchiev D and Van Rosmalen GM. Review: Nucleation in Solutions Revisited. Cryst Res Technol 2003; 38: 555–574.Google Scholar
  60. Kerns EH, Li C, Petusky S, Farris M, Ley R, and Jupp P. Combined Application of Parallel Artificial Membrane Permeability Assay and Caco-2 Permeability Assays in Drug Discovery. J Pharm Sci 2004; 93: 1440–1453.PubMedGoogle Scholar
  61. Koks C, Meenhorst P, Bult A, and Beijnen J. Itraconazole Solution: Summary of Pharmacokinetic Features and Review of Activity in the Treatment of Fluconazole-resistant Oral Candidosis in HIV-infected Persons. Pharmacol Res 2002; 46: 195–201.PubMedGoogle Scholar
  62. Kola I and Landis J. Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Rev Drug Discov 2004; 2: 711–715.Google Scholar
  63. Krill SK, Fort JJ, Law D, Schmitt EA, and Qiu Y. Inhibitors of Crystallization in a Solid Dispersion. International Patent Appl 2001: WO 0134119 A2.Google Scholar
  64. Kuentz M, Nick S, Parrott N, and Roethlisberger D. A Strategy for Preclinical Formulation Development Using GastroPlus as Pharmacokinetic Simulation Tool and a Statistical Screening Design Applied to a Dog Study.Eur J Pharm Sci 2006; 27: 91–99.PubMedGoogle Scholar
  65. Lee Y, Zocharski PD, and Samas B. An Intravenous Formulation Decision Tree for Discovery Compound Formulation Development. Int J Pharm 2003; 253: 111–119.PubMedGoogle Scholar
  66. Leuner C and Dressman J. Improving Drug Solubility for Oral Delivery using Solid Dispersion. Eur J Pharm Biopharm 2000; 50: 47–60.PubMedGoogle Scholar
  67. Lipinski CA. Avoiding Investment in Doomed Drugs. Curr Drug Discov 2001; 1: 17–19.Google Scholar
  68. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv Drug Deliv Rev 1997; 23: 3–25.Google Scholar
  69. Liu R. Water-insoluble Drug Formulation. Interpharm Press, Englewood, CO, 2000.Google Scholar
  70. Liu R. Meeting of the American Association of Pharmaceutical Scientists (AAPS)—Roundtable: Challenges and New Approaches to the Formulation of Poorly Water-Soluble Compounds for the Support of Toxicology Studies, Meeting of the American Association of Pharmaceutical Scientists (AAPS), Nashville, Tennessee, November 6–10, 2005.Google Scholar
  71. Loftsson T and Brewster M. Pharmaceutical Applications of Cyclodextrins. I. Drug Solubilization and Stabilization. J Pharm Sci 1996; 85: 1017–1025.PubMedGoogle Scholar
  72. Loftsson T and Brewster M. Cyclodextrins as Pharmaceutical Excipients. Pharmaceut Technol Europe 1997; 9: 26–34.Google Scholar
  73. Loftsson T, Brewster ME, and Masson M. Role of Cyclodextrins in Improving Oral Drug Delivery. Am J Drug Deliv 2004; 2: 261–275.Google Scholar
  74. Mahmood I. Estimation of Absorption Rate Constant (Ka) following Oral Administration by Wagner-Nelson, Loo-Riegelman, and Statistical Moments in the Presence of a Second Peak. Drug Metab Drug Interact 2004; 20: 85–100.Google Scholar
  75. Masungi C, Borremans C, Willems B, Mensch J, Van Dijck A, Augustijns P, Brewster M, and Noppe M. Usefulness of a Novel CACO-2 Cell Perfusion System I. In Vitro Prediction of the Absorption Potential of Passively Diffused Compounds.J Pharm Sci 2004; 93: 2507–2521.PubMedGoogle Scholar
  76. Noyes AA and Whitney WR. The Rate of Solution of Solid Substances in their Own Solutions. J Am Chem Soc 1897; 19: 930–934.Google Scholar
  77. Parrott N, Paquereau N, Coassolo P, and Lave T. An Evaluation of the Utility of Physiologically Based Models of Pharmacokinetics in Early Discovery. J Pharm Sci 2005; 94: 2327–2343.PubMedGoogle Scholar
  78. PDR. Physician's Desk Reference, Fifty-seventh Edition. Medical Economics Company, Montvale, NJ, 2003.Google Scholar
  79. Peeters J, Neeskens P, Tollenaere J, and Van Remoortere P. Characterization of the Interaction of 2-Hydroxypropyl-β-cyclodextrin with Itraconazole at pH 2, 4 and 7. J Pharm Sci 2002; 91: 1414–1422.PubMedGoogle Scholar
  80. Peeters J, Vandecruys R, and Brewster M. The Use of Supersaturation Studies in Early Pharmaceutical Development. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Salt Lake City, Utah, USA, October 26–30, 2003.Google Scholar
  81. Pellet MA, Castellano S, Hadgraft J, and Davis AF. The Penetration of Supersaturated Solutions of Piroxicam across Silicon Membranes and Human Skin In Vitro. J Control Rel 1997; 46: 205–214.Google Scholar
  82. Pellet MA, Davis AF, and Hadgraft J. Effect of Supersaturation on Membrane Transport: 2 Piroxicam. Int J Pharm 1994; 111: 1–6.Google Scholar
  83. Pellet MA, Roberts MS, and Hadgraft J. Supersaturated Solutions Evaluated with an In Vitro Stratum Corneum Tape Stripping Technique. 1997; 151: 91–98.Google Scholar
  84. Pitha J and Teruhiko H. Effect of Ethanol on Formation of Inclusion Complexes of Hydroxypropyl Cyclodextrins with Testosterone or with Methyl Orange.Int J Pharm 1992; 243–251.Google Scholar
  85. Pitha J, Teruhiko H, Torres-Labandeira J, and Irie T. Preparation of Drug-Hydroxypropyl Cyclodextrin Complexes by a Method Using Ethanol or Aqueous Ammonium Hydroxide as Cosolubilizers. Int J Pharm 1992; 80: 253–258.Google Scholar
  86. Prentis, R A, Lis, Y, and Walker, SR. Pharmaceutical Innovation by Seven UK-owned Pharmaceutical Companies.Br J Clin Pharmacol 1988; 25: 387–396.PubMedGoogle Scholar
  87. Rajewski RA, Traiger G, Bresnahan J, Jaberaboansari P, Stella VJ, and Thompson DO. Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin Derivatives.J Pharm Sci 1995; 84: 927–932.PubMedGoogle Scholar
  88. Rao VM and Stella VJ. When Can Cyclodextrins be Considered for Solubilization Purposes? J Pharm Sci 2003; 92: 927–932.PubMedGoogle Scholar
  89. Rowe RC, Sheskey PJ, and Owen S (Eds). Handbook of Pharmaceutical Excipients, Fifth Edition. Pharmaceutical Press and the American Pharmsists Association, London, 2006.Google Scholar
  90. Schulze JDR, Waddington WA, Ell, PJ, Parsons GE, Coffin MD, and Basit AW. Concentration-Dependent Effects of Polyethylene Glycol 400 on Gastrointestinal Transit and Drug Absorption.Pharm Res 2003; 20: 1984–1888.PubMedGoogle Scholar
  91. Serajuddin AT. Solid Dispersion of Poorly Water-soluble drugs. Early Promises, Subsequent Problems and Recent Breakthroughs. J Pharm Sci 1999; 88: 1058–1066.PubMedGoogle Scholar
  92. Singh S. Preclinical Pharmacokinetics: An Approach Towards Safer and Efficacious Drugs.Curr Drug Metab 2006; 7: 165–182.PubMedGoogle Scholar
  93. Steinberg M, Borzelleca JF, Enters EK, Kinoshita FK, Loper A, Mitchell DB, Tamulinas CB, and Weiner ML. A New Approach to the Safety Assessment of Pharmaceutical Excipients.Reg Toxicol Pharmacol 1996; 24: 149–154.Google Scholar
  94. Stoner C, Cleton A, Johnson K, Oh D, Hallak H, Brodfuehrer J, Surendran N, and Han H. Integrated Oral Bioavailability Projection Using In Vitro Screening Data as a Selection Tool. Int J Pharm 2004; 269: 241–249.PubMedGoogle Scholar
  95. Stoner C, Gifford E, Stankoic C, Lepsy C, Brodfuehrer J, Prasad J, and Surendran N. Implementation of an ADME Enabling Selection and Visualization Tool for Drug Discovery.J Pharm Sci 2004; 93: 1131–1141.PubMedGoogle Scholar
  96. Strickley RG. Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)—Part I. PDA J Pharm Sci Technol 1999; 53: 324–349.PubMedGoogle Scholar
  97. Strickley RG. Solubilizing Excipients in Oral and Liquid Formulations. Pharm Res 2004; 21: 201–230.PubMedGoogle Scholar
  98. Sun D, Yu L, Hussain M, Wall D, Smith R, and Amidon G. In Vitro Testing of Drug Absorption for Drug ‘Developability’ Assessment: Forming an Interface between In Vitro Preclinical Data and Clinical Outcome. Curr Opin Drug Discov Develop 2004; 7: 75–85.Google Scholar
  99. Sweetana S and Akers MJ. Solubility Principles and Practices for Parenteral Drug Dosage Form Development. PDA J Pharm Sci Technol 1996; 50: 330–342.PubMedGoogle Scholar
  100. Taylor LS and Zografi G. Spectroscopic Characterization of Interactions between PVP and Indomethacin in Amorphous Molecular Dispersions. Pharm Res 1997; 14: 1691–1698.PubMedGoogle Scholar
  101. Thompson DO. Cyclodextrins—Enabling Excipients: Their Present and Future Use in Pharmaceuticals. Crit Rev Therap Drug Carrier Syst 1997; 14: 1–104.Google Scholar
  102. Tissel AL. Handbook on Injectable Drugs, Eleventh Edition. American Society of Heath System Pharmacists, Bethesda, MD, 2001.Google Scholar
  103. Uekama K. Cyclodextrins in Drug Delivery System.Adv Drug Del Rev 1999; 36: 1–2.Google Scholar
  104. Uekama K, Hirayama F, and Irie T. Cyclodextrin Drug Carrier Systems. Chem Rev 1998; 98: 2045–2076.PubMedGoogle Scholar
  105. Valvani SC, Yalkowsky SH, and Roseman TJ. Solubility and Partitioning: IV Aqueous Solubility and Octanol-Water Partition Coefficients of Liquid Non-Electrolytes.J Pharm Sci 1981; 70: 502–507.PubMedGoogle Scholar
  106. Van Breemen R and Li Y. Caco-2 Cell Permeability Assays to Measure Drug Absorption. Expert Opin Drug Metab Toxicol 2005; 1: 175–185.PubMedGoogle Scholar
  107. Van de Waterbeemd H, and Gifford E. ADMET In Silico Modelling: Towards Prediction Paradise? Nature Rev Drug Discov 2003; 192–204.Google Scholar
  108. Van Dijck A, Masungi C, Mensch J, Borremans C, Willems B, Mackie C, Brewster M, and Noppe, M. Parallel Artificial Membrane Permeability Assay (PAMPA) Combined with a 10-Day Multiscreen CACO-2 Cell Culture for Prediction of Passive and Active Absorption of Drugs. 2003 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Salt Lake City, Utah, USA, October 26–30, 2003.Google Scholar
  109. Van Gelder J. EUFEPS Conference: When Poor Water Solubility Becomes an Issue: From Early Stage to Proof of Principle, Verona, Italy, April 26–27, 2006.Google Scholar
  110. Veng PP. Novel Deconvolution Method for Linear Pharmacokinetic Systems with Polyexponential Impulse Response.J Pharm Sci 1980; 69: 312–318.Google Scholar
  111. Veng PP. Novel Approach to Bioavailability Testing: Statistical Method for Comparing Drug Input Calculated by a Least-square Deconvolution Technique. J Pharm Sci 1980a; 69: 318–324.Google Scholar
  112. Weiner M and Bernstein IL. Adverse Reactions to Drug Formulation Agents: A Handbook of Excipients. Marcel Dekker, New York, NY, 1989.Google Scholar
  113. Weiner ML and Kotkoskie LA. Excipient Toxicity and Safety. Marcel Dekker, New York, NY, 2000.Google Scholar
  114. Wu S and Hopkins W. Characteristics of D-α-Tocopheryl PEG 100 Succinate for Applications as an Absorption Enhancer in Drug Delivery Systems. Pharm Tech 1999; 23: 52–68.Google Scholar
  115. Yalkowsky SH and Valvani S. Solubility and Partitioning I: Solubility of Non-Electrolytes in Water. J Pharm Sci 1980; 69: 912–922.PubMedGoogle Scholar
  116. Yang Z, Zadjura L, D'Arienzo C, Marino A, Santone K, Klunk L, Greene D, Lin P, Colonno R, Wang T, Meanwell N, and Hansel S. Preclinical Pharmacokinetics of a Novel HIV-1 Attachment Inhibitor BMS-378806 and Prediction of its Human Pharmacokinetics. Biopharm Drug Disp 2005; 26: 387–402.Google Scholar
  117. Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm Res 1997; 14: 763–766.PubMedGoogle Scholar
  118. Yu L. An Integrated Model for Determining Causes for Poor Oral Drug Absorption. Pharm Res 1999; 16: 1883–1887.PubMedGoogle Scholar
  119. Yu L, Amidon G, Polli J, Zhao H, Mehta M, Conner D, Shah VP, Lesko L, Chen M, Lee VL, and Hussain AS. Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions. Pharm Res 2002; 19: 921–925.PubMedGoogle Scholar
  120. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Boutina D, Beck G, Sherborne B, Cooper J, and Platts JA. Evaluation of Human Intestinal Data and Subsequent Derivation of a Quantitative Structure-Activity Relationship (QSAR) with the Abraham Descriptors.J Pharm Sci 2001; 90: 749–784.PubMedGoogle Scholar
  121. Zhu C, Jiang L, Chen T, and Hwang K. A Comparative Study of Artificial Membrane Permeability Assay for High Throughput Profiling of Drug Absorption Potential. Eur J Med Chem 2002; 37: 399–407.PubMedGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • MARCUS E. BREWSTER
    • 1
  • CLAIRE MACKIE
    • 2
  • MARC NOPPE
    • 2
  • ANN LAMPO
    • 3
  • THORSTEINN LOFTSSON
    • 4
  1. 1.Chemical and Pharmaceutical Development, Johnson & JohnsonPharmaceutical Research and DevelopmentBeerseBELGIUM
  2. 2.Research and Early Development, Johnson & JohnsonPharmaceutical Research and DevelopmentBeerseBELGIUM
  3. 3.Preclinical Development, Johnson & JohnsonPharmaceutical Research and DevelopmentBeerseBELGIUM
  4. 4.Faculty of PharmacyThe University of IcelandReykjavikICELAND

Personalised recommendations